50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
NYSE:PATH

UiPath - PATH Stock Forecast, Price & News

$12.87
-0.17 (-1.30%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.51
$13.13
50-Day Range
$12.87
$21.94
52-Week Range
$12.21
$59.57
Volume
7.84 million shs
Average Volume
9.51 million shs
Market Capitalization
$7.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.97

UiPath MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
94.0% Upside
$24.97 Price Target
Short Interest
Bearish
6.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of UiPath in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$3.13 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Business Services Sector

123rd out of 329 stocks

Prepackaged Software Industry

87th out of 226 stocks

PATH stock logo

About UiPath (NYSE:PATH) Stock

UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Its platform combines artificial intelligence with desktop recording, back-end mining of both human activity and system logs, and intuitive visualization tools, which enables users to discover, analyze, and identify processes to automate in a centralized portal; offers low-code development environments that allows users in an organization to create attended and unattended automations without any prior knowledge of coding; deploys robots in highly immersive attended experiences or in standalone, unattended modes behind the scenes, and can leverage native connectors built for commonly used line-of-business applications; offers centralized tools designed to manage, test, and deploy automations and ML models across the enterprise; allows customers to manage long running processes that orchestrate work between robots and humans; and enable users to track, measure, and forecast the performance of automation in their enterprise and help businesses ensure compliance with business standards. In addition, the company provides maintenance and support for its software, as well as professional services, such as training and implementation services to facilitate the adoption of its platform. It serves banking, healthcare, financial services, and government entities. UiPath Inc. was founded in 2005 and is headquartered in New York, New York.

Receive PATH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UiPath and its competitors with MarketBeat's FREE daily newsletter.

PATH Stock News Headlines

3 Deflation Enablers Stocks that Can Thrive in a Recession (PATH)
Deflation enablers are companies that help organizations cut costs, grow efficiencies, and optimize performance during uncertain times.
1 SaaS Stock to Buy This Fall and 1 to Sell
UiPath Inc. (NYSE:PATH) CFO Sells $450,600.00 in Stock
Stock Traders Buy High Volume of UiPath Put Options (NYSE:PATH)
UiPath to Host Investor Day on September 27, 2022
Is It Time to Sell UiPath Stock?
3 Things About UiPath That Smart Investors Know
See More Headlines
Receive PATH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UiPath and its competitors with MarketBeat's FREE daily newsletter.

PATH Company Calendar

Last Earnings
9/06/2022
Today
9/24/2022
Next Earnings (Estimated)
12/14/2022
Fiscal Year End
1/31/2023

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
2,863
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$24.97
High Stock Price Forecast
$64.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+94.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
17 Analysts

Profitability

Net Income
$-525,590,000.00
Pretax Margin
-40.93%

Debt

Sales & Book Value

Annual Sales
$892.25 million
Book Value
$3.40 per share

Miscellaneous

Free Float
371,071,000
Market Cap
$7.01 billion
Optionable
Not Optionable
Beta
0.11

Social Links


Key Executives

  • Mr. Daniel Solomon Dines (Age 50)
    Co-Founder, Co-CEO & Chairman
    Comp: $669.65k
  • Mr. Ashim GuptaMr. Ashim Gupta (Age 43)
    Chief Financial Officer
    Comp: $642.52k
  • Mr. Ted KummertMr. Ted Kummert (Age 59)
    Exec. VP of Products & Engineering
    Comp: $672.56k
  • Mr. Robert Enslin (Age 59)
    Co-Chief Exec. Officer
  • Mr. Marius Tirca
    Co-Founder & CTO
  • Ms. Kelsey Doherty Turcotte
    Sr. VP of Investor Relations
  • Mr. Brad C. BrubakerMr. Brad C. Brubaker (Age 58)
    Gen. Counsel, Chief Legal Officer & Sec.
  • Mr. Robert B. Patrick (Age 50)
    Chief Marketing Officer
  • Mr. Christopher Townsend
    VP of Federal Sales
  • Mr. Vijay Khanna
    Chief Corp. Devel. Officer













PATH Stock - Frequently Asked Questions

Should I buy or sell UiPath stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UiPath in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PATH shares.
View PATH analyst ratings
or view top-rated stocks.

What is UiPath's stock price forecast for 2022?

17 brokerages have issued twelve-month price objectives for UiPath's stock. Their PATH share price forecasts range from $14.00 to $64.00. On average, they predict the company's stock price to reach $24.97 in the next twelve months. This suggests a possible upside of 94.0% from the stock's current price.
View analysts price targets for PATH
or view top-rated stocks among Wall Street analysts.

How have PATH shares performed in 2022?

UiPath's stock was trading at $43.13 at the start of the year. Since then, PATH stock has decreased by 70.2% and is now trading at $12.87.
View the best growth stocks for 2022 here
.

When is UiPath's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 14th 2022.
View our PATH earnings forecast
.

How were UiPath's earnings last quarter?

UiPath Inc. (NYSE:PATH) posted its quarterly earnings data on Tuesday, September, 6th. The healthcare company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.09. The healthcare company had revenue of $242.22 million for the quarter, compared to analyst estimates of $230.68 million. UiPath had a negative trailing twelve-month return on equity of 19.19% and a negative net margin of 42.98%. The company's revenue for the quarter was up 23.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.17) EPS.

What guidance has UiPath issued on next quarter's earnings?

UiPath updated its third quarter 2023 earnings guidance on Tuesday, September, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $243.00 million-$245.00 million, compared to the consensus revenue estimate of $269.60 million.

What are Wall Street analysts saying about UiPath stock?
Here are some recent quotes from research analysts about UiPath stock:
  • 1. The analyst says his price target cut reflects his updated discount cash flow model, but he also recommends that investors take advantage of the broad weakness that has impacted software as an attractive buying opportunity to buy UiPath for its long-term compounding growth story. Tillman further points to the company's record net new ARR, "constructive" Q4 outlook, and a variety of new innovations in the pipeline such as automation bots for Mac users, multi-cloud multi-platform capabilities, automation cloud traction, and task/process mining." (12/9/2021)
  • 2. The analyst notes UiPath delivered another "solid" beat across top-line metrics for Q3, including a quarterly record for net new ARR and total revenue growth of +50%. While Q3 was strong, the full-year ARR guide increased by $22M, implying a modest $2M raise post the $20M Q3 beat, Turrin adds. With Q3 results coming in clean, he expects investor conversation will focus in on what's ahead for new business activity into a seasonally strong Q4 and the potential for pent-up automation demand in a tight labor market heading into fiscal 2023. While UiPath continues to blaze a trail toward broad-based RPA adoption, current valuation levels and a rapidly evolving market backdrop leave the analyst more balanced on shares. " (12/9/2021)
When did UiPath IPO?

(PATH) raised $990 million in an IPO on Wednesday, April 21st 2021. The company issued 21,300,000 shares at a price of $43.00-$50.00 per share. Morgan Stanley, JPMorgan, BofA Securities, Credit Suisse, Barclays and Wells Fargo Securities acted as the underwriters for the IPO and SMBC Nikko, BMO Capital Markets, Mizuho Securities USA, KeyBanc Capital Markets, TD Securities (USA), Truist SecuritiesCowen, Evercore Group, Macquarie Capital (USA), Nomura, RBC Capital Markets, Canaccord Genuity, D. A. Davidson & Co., Oppenheimer & Co. and Needham & Co. were co-managers.

What is UiPath's stock symbol?

UiPath trades on the New York Stock Exchange (NYSE) under the ticker symbol "PATH."

Who are UiPath's major shareholders?

UiPath's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (6.90%), Sumitomo Mitsui Trust Holdings Inc. (4.41%), Nikko Asset Management Americas Inc. (4.21%), Goldman Sachs Group Inc. (1.77%), Clearbridge Investments LLC (1.42%) and FMR LLC (1.32%). Insiders that own company stock include Ashim Gupta, Brad Brubaker, Daniel Dines, East Fund 2013 Sca Sic Digital, Hitesh Ramani, Kimberly Hammonds, Laela Sturdy, Philippe Botteri, Rich Wong, Ted Kummert and Thomas Neergaard Hansen.
View institutional ownership trends
.

How do I buy shares of UiPath?

Shares of PATH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UiPath's stock price today?

One share of PATH stock can currently be purchased for approximately $12.87.

How much money does UiPath make?

UiPath (NYSE:PATH) has a market capitalization of $7.01 billion and generates $892.25 million in revenue each year. The healthcare company earns $-525,590,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does UiPath have?

The company employs 2,863 workers across the globe.

Does UiPath have any subsidiaries?
The following companies are subsidiares of UiPath: Magna View BV, Process Gold International BV, ProcessGold, StepShot, UiPath AB, UiPath Australia Pty Ltd, UiPath Canada, UiPath China - Shanghai, UiPath France SAS, UiPath GMBH, UiPath Hong Kong, UiPath KK, UiPath Limited, UiPath Ltd. (India), UiPath Ltd. (SG), UiPath Ltd. (UK), UiPath Netherlands B.V., UiPath Netherlands Holding B.V., UiPath SRL, UiPath South Korea, and UiPath Switzerland GmbH.
Read More
How can I contact UiPath?

UiPath's mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The official website for the company is www.nupathe.com. The healthcare company can be reached via phone at 844-432-0455 or via email at investor.relations@uipath.com.

This page (NYSE:PATH) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.